- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01216657
Trial of Single Agent Sunitinib for Patients With Chemo-refractory Metastatic Melanoma
An Open-label, Uncontrolled Phase II Trial of Single Agent Sunitinib (SU 11248) for Patients With Chemo-refractory Metastatic Melanoma
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This is a single agent 2-step phase 2 study with a one-year follow-up to evaluate the antitumor activity of Sunitinib administered in treatment cycles of 6 weeks duration (4 weeks treatment and 2 weeks rest) in patients with chemo-refractory melanoma. If the first step shows sufficient efficacy and tolerability the study will continue to step 2. Treatment will continue for 9 months or until disease progression or until intolerable adverse events occur. Subsequently the patients will be followed up for 1 year. Tumor assessment will be performed at baseline, at the end of cycle 1,2,3 and subsequently at the end of every uneven cycle (5,7,9,…).
A total of 40 patients will be enrolled in this trial.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
-
Frankfurt/Main, Tyskland, 60488
- Krankenhaus Nordwest
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Male and female patients aged 18 years and older.
- Diagnosis of unresectable (Stage III) or metastatic (Stage IV), histologically or cytologically proven, melanoma without clinically meaningful surgical or radiotherapeutical options except for mucosal or ocular origin of the primary tumor.
- Subjects must have completed a first or second line chemotherapy or be progressed under chemotherapeutic treatment. The previous treatment must have included DTIC alone or in combination
- Performance status of 0 to 2 on the ECOG scale
- Life expectancy > 12 weeks.
- Patients must be able to swallow Sunitinib capsules.
- Evidence of measurable disease according to the RECIST criteria
- Prior radiation therapy allowed if completed at least 2 weeks and any major surgery allowed if completed at least 4 weeks prior to first dose of Sunitinib.
- Resolution of all acute toxic side effects of prior therapy or surgical procedures to grade < 1 NCI-CTC (except for laboratory values).
Adequate organ function including the following:
- platelets > 100 x 109/L
- hemoglobin > 8 g/dl
- absolute neutrophils count (AGC) > 1.5 x 109/L.
Hepatic:
- bilirubin <=1.5 times upper limit of normal (ULN)
- aspartate transaminase (AST) and alanine transaminase (ALT) <=2.5 times normal (AST and ALT <=5.0 times normal is acceptable if liver function abnormalities are due to underlying malignancy).
- INR < 1.5 or a PTT within normal limits.
- Subjects must not have any evidence of a bleeding diathesis.
Renal:
- Serum creatinine < 1.5 x ULN
- serum calcium < 1.2 mg/dl.
- Pancreatic:
- Serum lipase and amylase within normal range.
- Signed and dated informed consent
Exclusion Criteria:
- Prior treatment with ras-raf-MEK-ERK signaling pathway inhibitors (including trastuzumab, sorafenib, farnesyl transferase inhibitors or MEK inhibitors), or treatment with drugs which target VEGF (such as bevacizumab).
- Radiotherapy, except palliative radiotherapy during study participation as described.
- Known active infection (i.e. HIV, chronic hepatitis B or C, at the discretion of the investigator)
- History of organ allograft or stem cell transplantation.
- Coexisting second malignancy (excluding basal or squamous cell carcinoma of the skin, superficial bladder cancer and in situ carcinoma of the cervix with no evidence of recurrence) or history of prior malignancy
- Bowel obstruction, history or presence of inflammatory enteropathy or extensive intestinal resection (> hemicolectomie or extensive small intestine resection with chronic diarrhea), Crohn's disease, ulcerative colitis.
- Current history of chronic diarrhea defined as persisting diarrhea for more than 3 weeks at study entry due to any reason.
Any of the following events prior to starting the trial treatment: *clinically evident congestive heart failure, as defined by New York Health Association (NYHA) > class II
- Ongoing cardiac dysrhythmias of NCI CTCAE grade ≥2
- Atrial fibrillation of any grade, or prolongation of the QTc interval to >450 msec for males or >470 msec for females.
- Subjects on beta-blockers and digoxin must be monitored closely
- QT-interval > 450 msec
- Risk factors for torsade-de-pointes-tachycardia (i.e.. Hypokalaemia, congenital Long-QT-syndrome)
- Active coronary artery disease or ischemia (myocardial infarction within the last 6 months prior to study entry)
- Coronary/peripheral artery bypass graft
- Cerebrovascular accident or transient ischemic attack
- Active disseminated intravascular coagulation, or history of clinically significant bleeding within the past 6 months, including gross hemoptysis or haematuria, or underlying coagulopathy
- Hypertension that cannot be controlled by medications (>150/100 mmHg despite optimal medical therapy).
- Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with trial participation or trial drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into the trial.
- Participation in any other clinical trial within the last 3 weeks.
- Pregnant or lactating women.
- Known allergic/hypersensitivity reaction to any of the components of the treatment, or known drug abuse/alcohol abuse.
- Active CNS metastatic or meningeal tumors.
- Patients with seizure disorders requiring medication (such as antiepileptics, the use of carbamazepine, phenytion an phenobarbital is prohibited).
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: sunitinib
50 mg Sunitinib daily for 4 weeks, then 2 weeks without treatment
|
50 mg oral, daily, for 4 weeks, then 2 weeks without treatment, repeat at d43
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
clinical benefit rate cycle 1-3
Tidsram: tumor assessment every 6 weeks
|
clinical benefit rate defined as a CR + PR + SD > 4 months duration
|
tumor assessment every 6 weeks
|
clinical benefit rate cycle 4 and more
Tidsram: tumor assessment every 12 weeks
|
clinical benefit rate defined as a CR + PR + SD > 4 months duration
|
tumor assessment every 12 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
response rate cycle 1-3
Tidsram: tumor assessment every 6 weeks
|
response rate defined as CR+PR
|
tumor assessment every 6 weeks
|
progression free survival
Tidsram: follow-up one year
|
follow-up one year
|
|
overall survival
Tidsram: follow-up for one year
|
follow-up for one year
|
|
response rate cycle 4 and more
Tidsram: every 12 weeks
|
response rate defined as CR+PR
|
every 12 weeks
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Elke Jäger, Prof. Dr., Krankenhaus Nordwest
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Neoplasmer efter histologisk typ
- Neoplasmer
- Neuroektodermala tumörer
- Neoplasmer, könsceller och embryonala
- Neoplasmer, nervvävnad
- Neuroendokrina tumörer
- Nevi och melanom
- Melanom
- Läkemedels fysiologiska effekter
- Molekylära mekanismer för farmakologisk verkan
- Enzyminhibitorer
- Antineoplastiska medel
- Angiogeneshämmare
- Angiogenesmodulerande medel
- Tillväxtämnen
- Tillväxthämmare
- Proteinkinashämmare
- Sunitinib
Andra studie-ID-nummer
- S379 SUMA
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Chemo-refractory Melanoma
-
Vanderbilt University Medical CenterAvslutadBröstcancer | Kemoterapirelaterad kognitiv funktionsnedsättning | Chemo dimma | Chemo hjärna | ChemobrainFörenta staterna
-
Diwakar DavarMerck Sharp & Dohme LLC; Gateway for Cancer ResearchHar inte rekryterat ännuPD-1 Refractory Advanced MelanomFörenta staterna
-
European Society for Blood and Marrow TransplantationMallinckrodtAvslutadSteroid Refractory GVHDSpanien, Storbritannien, Sverige, Italien, Israel, Frankrike, Danmark, Tyskland, Polen, Kalkon, Rumänien, Belgien, Grekland, Ryska Federationen
-
ElsaLys BiotechHar inte rekryterat ännu
-
Agenus Inc.AvslutadAvancerad solid cancer | Advanced Solid Cancers Refractory to PD-1Förenta staterna
-
MaaT PharmaRekryteringSteroid Refractory GVHD | Tarm GVHDFrankrike
-
Yi-Lun WangAvslutadSteroid Refractory GVHDTaiwan
-
H. Lee Moffitt Cancer Center and Research InstituteTurnstone Biologics, Corp.RekryteringMetastaserande melanom | Konjunktivalt melanom | Okulärt melanom | Ooperabelt melanom | Uveal melanom | Kutant melanom | Slemhinnemelanom | Iris melanom | Akralt melanom | Icke-kutant melanomFörenta staterna
-
Second Affiliated Hospital, School of Medicine,...OkändTherapeutic Mechanism of Antidepressants for Refractory FDKina
Kliniska prövningar på Sunitinib
-
AGO Study GroupPhilipps University Marburg Medical Center; HSK Reasearch GmbH WiesbadenAvslutadPlatina eldfast epitelial äggstockscancer | Primär cancer i bukhinnan | Cancer i äggledarenTyskland
-
Cogent Biosciences, Inc.RekryteringMetastaserande cancer | Avancerade gastrointestinala stromala tumörerFörenta staterna, Korea, Republiken av, Spanien, Storbritannien, Australien, Frankrike, Italien, Nederländerna, Taiwan, Tyskland, Danmark, Hong Kong, Kanada, Sverige, Norge, Mexiko, Tjeckien, Argentina, Ungern, Brasilien, Chile, Polen
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)AvslutadNjurcancerFörenta staterna
-
PfizerAvslutadBröstneoplasmerFörenta staterna
-
National Cancer Institute (NCI)AvslutadÅterkommande metastaserande skivepitelcancer med ockult primär | Återkommande skivepitelcancer i hypofarynx | Återkommande skivepitelcancer i struphuvudet | Återkommande skivepitelcancer i läpp- och munhålan | Återkommande skivepitelcancer i orofarynx | Återkommande skivepitelcancer i paranasal... och andra villkorFörenta staterna
-
PfizerAvslutadGastrointestinala stromala tumörerKorea, Republiken av
-
California Pacific Medical Center Research InstitutePfizer; University of California, San FranciscoAvslutadMetastaserande melanomFörenta staterna
-
National Cancer Institute (NCI)AvslutadSteg I multipelt myelom | Steg II multipelt myelom | Steg III multipelt myelom | Refraktärt multipelt myelomFörenta staterna
-
PfizerAvslutadGastrointestinala stromala tumörerFörenta staterna, Tjeckien, Frankrike
-
National Cancer Institute (NCI)AvslutadSteg IV Ovariepitelialcancer | Återkommande epitelial cancer i äggstockarna | Återkommande primär peritonealcancer | Steg IV Primär peritonealcancer | Återkommande äggledarcancer | Stadium IIIA Äggledarcancer | Stadium IIIB Äggledarcancer | Stadium IIIC Äggledarcancer | Stadium IV Äggledarcancer | Stadium... och andra villkorKanada